| __timestamp | BioMarin Pharmaceutical Inc. | Viridian Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 129764000 | 3243000 |
| Thursday, January 1, 2015 | 152008000 | 2472000 |
| Friday, January 1, 2016 | 209620000 | 2548000 |
| Sunday, January 1, 2017 | 241786000 | 19623000 |
| Monday, January 1, 2018 | 315264000 | 30421000 |
| Tuesday, January 1, 2019 | 359466000 | 32793999 |
| Wednesday, January 1, 2020 | 524272000 | 28304000 |
| Friday, January 1, 2021 | 470515000 | 620000 |
| Saturday, January 1, 2022 | 483669000 | 755000 |
| Sunday, January 1, 2023 | 577065000 | 1322000 |
Igniting the spark of knowledge
In the competitive landscape of pharmaceuticals, understanding cost dynamics is crucial. BioMarin Pharmaceutical Inc. and Viridian Therapeutics, Inc. offer a fascinating study in contrasts over the past decade. From 2014 to 2023, BioMarin's cost of revenue surged by approximately 345%, peaking in 2023. This growth reflects BioMarin's expanding operations and market reach. In contrast, Viridian's cost of revenue exhibited volatility, with a notable spike in 2017 and 2018, followed by a sharp decline. By 2023, Viridian's costs were a mere fraction of BioMarin's, highlighting different strategic paths. BioMarin's consistent upward trend suggests a focus on scaling, while Viridian's fluctuations may indicate strategic pivots or market challenges. This analysis underscores the importance of cost management in sustaining competitive advantage in the pharmaceutical industry.
Cost of Revenue: Key Insights for AbbVie Inc. and BioMarin Pharmaceutical Inc.
Bristol-Myers Squibb Company vs BioMarin Pharmaceutical Inc.: Efficiency in Cost of Revenue Explored
Analyzing Cost of Revenue: Gilead Sciences, Inc. and Viridian Therapeutics, Inc.
Cost of Revenue Comparison: Zoetis Inc. vs BioMarin Pharmaceutical Inc.
Analyzing Cost of Revenue: GSK plc and BioMarin Pharmaceutical Inc.
Cost Insights: Breaking Down Teva Pharmaceutical Industries Limited and Viridian Therapeutics, Inc.'s Expenses
Analyzing Cost of Revenue: Biogen Inc. and BioMarin Pharmaceutical Inc.
BioMarin Pharmaceutical Inc. vs Jazz Pharmaceuticals plc: Efficiency in Cost of Revenue Explored
Analyzing Cost of Revenue: BioMarin Pharmaceutical Inc. and Corcept Therapeutics Incorporated
Analyzing Cost of Revenue: BioMarin Pharmaceutical Inc. and HUTCHMED (China) Limited
Cost Insights: Breaking Down BioMarin Pharmaceutical Inc. and Amphastar Pharmaceuticals, Inc.'s Expenses
Comparing Cost of Revenue Efficiency: Xenon Pharmaceuticals Inc. vs Viridian Therapeutics, Inc.